The Greatest Value of Personalized Medicine

Grant D. Lawless, RPh, MD, FACP

Video Categories: Value

Grant Lawless discusses the definition of value in personalized medicine from different perspectives
October 8, 2014

Risks with Cytoreductive Therapy

Hear Dr. Michaelis discuss cytoreductive therapy and the risk factor for patients with hemorrhage.Supported through funding from Incyte

August 29, 2018

How PD-L1 Biomarker Test Results Impact Clinical Management of Lung Cancer

Drs. Goeffrey Oxnard and Lauren Ritterhouse review how the results of PD-L1 testing influence the choices in first- or second-line immunotherapy or combination immunochemotherapy in patients with squamous or non-squamous non-small-cell lung cancer.